Filing Details

Accession Number:
0001104659-12-015908
Form Type:
4
Zero Holdings:
No
Publication Time:
2012-03-06 15:28:38
Reporting Period:
2012-03-02
Filing Date:
2012-03-06
Accepted Time:
2012-03-06 15:28:38
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1492426 Horizon Pharma Inc. HZNP Pharmaceutical Preparations (2834) 272179987
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1030575 Francois Jean Formela 25 First Street, Suite 303
Cambridge MA 02141
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2012-03-02 828,443 $3.62 3,688,294 No 4 P Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See Footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Warrants to Purchase Common Stock Acquisiton 2012-03-02 207,110 $3.62 207,110 $4.31
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
207,110 2012-03-02 2017-03-02 No 4 P Indirect
Footnotes
  1. Includes 789,828 shares of common stock purchased by Atlas Venture Fund VI, L.P., 14,462 shares of common stock purchased by Atlas Venture Fund VI GmbH & Co. KG and 24,153 shares of common stock purchased by Atlas Venture Entrepreneurs' Fund VI, L.P. Atlas Venture Associates VI, L.P. is the general partner of Atlas Venture Fund VI, L.P. and Atlas Venture Entrepreneurs' Fund VI, L.P. and the managing limited partner of Atlas Venture Fund VI GmbH & Co. KG. Each of the Filing Persons disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein. Mr. Formela disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Mr. Formela is a director of Issuer.
  2. Purchase price consists of the sum of (i) $3.59 (the closing bid price of the Issuer's common stock on 2/28/2012) and (ii) $0.03125.
  3. Includes 3,516,377 shares of common stock held by Atlas Venture Fund VI, L.P., 64,385 shares of common stock held by Atlas Venture Fund VI GmbH & Co. KG and 107,532 shares of common stock held by Atlas Venture Entrepreneurs' Fund VI, L.P. Atlas Venture Associates VI, L.P. is the general partner of Atlas Venture Fund VI, L.P. and Atlas Venture Entrepreneurs' Fund VI, L.P. and the managing limited partner of Atlas Venture Fund VI GmbH & Co. KG. Each of the Filing Persons disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein. Mr. Formela disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Mr. Formela is a director of Issuer.
  4. For each share of common stock of the Issuer purchased in the financing, a purchaser received a warrant to purchase 0.25 of a share of common stock of the Issuer. Includes warrants to purchase 197,456 shares of common stock purchased by Atlas Venture Fund VI, L.P., warrants to purchase 3,616 shares of common stock purchased by Atlas Venture Fund VI GmbH & Co. KG and warrants to purchase 6,038 shares of common stock purchased by Atlas Venture Entrepreneurs' Fund VI, L.P. Atlas Venture Associates VI, L.P. is the general partner of Atlas Venture Fund VI, L.P. and Atlas Venture Entrepreneurs' Fund VI, L.P. and the managing limited partner of Atlas Venture Fund VI GmbH & Co. KG. Each of the Filing Persons disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein. Mr. Formela disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Mr. Formela is a director of Issuer.